AU2002337916A1 - Modifier of the p53 pathway and methods of use - Google Patents
Modifier of the p53 pathway and methods of useInfo
- Publication number
- AU2002337916A1 AU2002337916A1 AU2002337916A AU2002337916A AU2002337916A1 AU 2002337916 A1 AU2002337916 A1 AU 2002337916A1 AU 2002337916 A AU2002337916 A AU 2002337916A AU 2002337916 A AU2002337916 A AU 2002337916A AU 2002337916 A1 AU2002337916 A1 AU 2002337916A1
- Authority
- AU
- Australia
- Prior art keywords
- modifier
- pathway
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4739—Cyclin; Prad 1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33873301P | 2001-10-22 | 2001-10-22 | |
US60/338,733 | 2001-10-22 | ||
US35760002P | 2002-02-15 | 2002-02-15 | |
US60/357,600 | 2002-02-15 | ||
PCT/US2002/033542 WO2003035833A2 (fr) | 2001-10-22 | 2002-10-21 | Modificateurs de la voie de passage de p53 et leurs procedes d'utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002337916A1 true AU2002337916A1 (en) | 2003-05-06 |
Family
ID=26991338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002337916A Abandoned AU2002337916A1 (en) | 2001-10-22 | 2002-10-21 | Modifier of the p53 pathway and methods of use |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002337916A1 (fr) |
WO (1) | WO2003035833A2 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ607886A (en) | 2003-03-19 | 2014-09-26 | Biogen Idec Inc | Nogo receptor binding protein |
WO2005019258A2 (fr) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions et methodes de traitement de maladies relatives au systeme immunitaire |
US8486893B2 (en) | 2004-06-24 | 2013-07-16 | Biogen Idec Ma Inc. | Treatment of conditions involving demyelination |
US20090054321A1 (en) * | 2005-04-18 | 2009-02-26 | O'neill Luke Anthony John | Polypeptides and use thereof |
JP2009502123A (ja) | 2005-07-08 | 2009-01-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Sp35抗体およびその使用 |
GB0620705D0 (en) | 2006-10-18 | 2006-11-29 | Opsona Therapeutics | Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds |
GB0620695D0 (en) * | 2006-10-18 | 2006-11-29 | Opsona Therapeutics | Composition and methods for the treatment of nurdegenerative disease |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
EP2982695B1 (fr) | 2008-07-09 | 2019-04-03 | Biogen MA Inc. | Compositions comprenant des anticorps anti-lingo ou leurs fragments |
WO2011034605A2 (fr) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations |
KR102142161B1 (ko) | 2012-05-14 | 2020-08-06 | 바이오젠 엠에이 인코포레이티드 | 운동 뉴런 관련 병태 치료용 lingo-2 길항제 |
JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Lingo‐1拮抗薬及び脱髄障害の治療のための使用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030108963A1 (en) * | 2001-07-25 | 2003-06-12 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer |
-
2002
- 2002-10-21 AU AU2002337916A patent/AU2002337916A1/en not_active Abandoned
- 2002-10-21 WO PCT/US2002/033542 patent/WO2003035833A2/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2003035833A2 (fr) | 2003-05-01 |
WO2003035833A3 (fr) | 2004-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002310256A1 (en) | Ppp2cs as modifiers of the p53 pathway and methods of use | |
AU2002352903A1 (en) | Mesoporous materials and methods | |
AU2002320058A1 (en) | Magnetic-nanoparticle conjugates and methods of use | |
AU2002364528A1 (en) | Bio-implant and method of making the same | |
AU2002315389A1 (en) | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof | |
AU2002314474A1 (en) | Grating structures and methods of making the grating structures | |
AU2002314466A1 (en) | Withasol and methods of use | |
AU2002324598A1 (en) | Trps as modifiers of the p53 pathway and methods of use | |
AU2002315388A1 (en) | Novel phenylamino-pyrimidines and uses thereof | |
EP1402262A4 (fr) | Map3ks utiles en tant que modificateurs de la voie p53 et methodes d'utilisation | |
AU2002239933A1 (en) | Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof | |
AU2002337916A1 (en) | Modifier of the p53 pathway and methods of use | |
AU2002359694A1 (en) | Compounds and methods | |
AU2002363938A1 (en) | Methods and use of motoneuronotropic factors | |
AU2002314874A1 (en) | Modifiers of the p53 pathway and methods of use | |
AU2002259238A1 (en) | Dwf12 and mutants thereof | |
AU2002303947A1 (en) | Pecis as modifiers of the p53 pathway and methods of use | |
AU2002303951A1 (en) | Glras as modifiers of the p53 pathway and methods of use | |
AU2002312283A1 (en) | Srpks as modifiers of the p53 pathway and methods of use | |
AU2002345486A1 (en) | Slc13as as modifiers of the p53 pathway and methods of use | |
AU2002357817A1 (en) | Klcs as modifiers of the p53 pathway and methods of use | |
AU2002360586A1 (en) | FLJ1115 AS MODIFIER OF THE Apaf-1 PATHWAY AND METHODS OF USE | |
AU2002330299A1 (en) | Antibody and use of the same | |
AU2002228426A1 (en) | Neurotonin and use thereof | |
AU2002258842A1 (en) | Hydrogenfluorides of aminosilanols and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |